中国医院用药评价与分析2024，Vol.24Issue(7)：856-861,6.DOI:10.14009/j.issn.1672-2124.2024.07.019
PEG-rhG-CSF与rhG-CSF预防肿瘤化疗相关中性粒细胞减少的有效性和安全性比较的系统评价和Meta分析
Systematic Review and Meta-Analysis on Efficacy and Safety of PEG-rhG-CSF and rhG-CSF in the Prevention of Chemotherapy-Related Neutropenia
摘要
Abstract
OBJECTIVE:To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)and rhG-CSF in the prevention of chemotherapy-related neutropenia.METHODS:PubMed,Embase,the Cochrane Library,CNKI,Wanfang Data and VIP databases were retrieved to collect randomized controlled trials of PEG-rhG-CSF and rhG-CSF in the prevention of chemotherapy-related neutropenia(intervention measures were PEG-rhG-CSF,control measures were rhG-CSF)until May 2023.Literature screening,information extraction and bias risk assessment were carried out by two researchers independently.Meta-analysis was performed by RevMan 5.3 statistical software.RESULTS:A total of 41 studies were included.Meta-analysis showed that compared with rhG-CSF,PEG-rhG-CSF could significantly reduce the incidence of neutropenia with fever(FN)after chemotherapy(OR=0.64,95%CI=0.51-0.81,P=0.0002)and the incidence of grade Ⅲ/Ⅳ neutropenia(OR=0.49,95%CI=0.35-0.69,P<0.0001),the differences were statistically significant;however,differences in the duration of grade Ⅲ/Ⅳ neutropenia(MD=-0.33,95%CI=-0.68-0.01,P=0.06),the recovery time of neutropenia(MD=-0.11,95%CI=-0.32-0.09,P=0.27),the incidence of bone pain or skeletal muscle pain(OR=0.81,95%CI=0.66-1.00,P=0.05)were not statistically significant.CONCLUSIONS:The efficacy of PEG-rhG-CSF in the prevention of FN and grade Ⅲ/Ⅳ neutropenia after chemotherapy is significantly better than that of rhG-CSF,and PEG-rhG-CSF is feasible as primary prevention.关键词
聚乙二醇化重组人粒细胞集落刺激因子/重组人粒细胞集落刺激因子/中性粒细胞减少/Meta分析Key words
Pegylated recombinant human granulocyte colony-stimulating factor/Recombinant human granulocyte colony-stimulating factor/Neutropenia/Meta-analysis分类
医药卫生引用本文复制引用
朱依雯,周伟贤,丁可,陈荣..PEG-rhG-CSF与rhG-CSF预防肿瘤化疗相关中性粒细胞减少的有效性和安全性比较的系统评价和Meta分析[J].中国医院用药评价与分析,2024,24(7):856-861,6.基金项目
2023年江苏省药品临床综合评价项目(No.KY20231613) （No.KY20231613）
常州市科技基础设施建设计划-常州市临床药学重点实验室项目(No.CM20223005) （No.CM20223005）
